7月9日盘中，中国生物制药（01177.HK）股价表现强劲，大涨5.03%，引发市场关注。截至发稿时，该股报5.59港元，成交额已超3.69亿港元。
消息面上，中国生物制药近日发布公告称，集团开发的"注射用重组人凝血因子VIIa N01"（商品名：安启新®）已获得中国国家药品监督管理局的上市批准。这是国内首个获批上市的国产重组人凝血因子VIIa类生物制品，用于治疗特定类型的先天性血友病患者的出血。
安启新是目前国内唯一通过III期临床试验确证疗效和安全性的重组人凝血因子VIIa产品。在一项多中心、单臂、开放的III期临床研究中，安启新显示出显著的疗效。研究结果显示，在551次可评估的出血事件中，止血有效率高达88.93%。这一突破性进展不仅标志着中国在生物制药领域的重要成就，也为血友病患者带来了新的治疗选择，有望显著提升公司在相关治疗领域的市场地位和竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.